Objective: The purpose of this study is to evaluate the safety and efficacy of transcatheter aortic valve implantation (TAVI) in patients with a severe stenotic bicuspid aortic valve (BAV) in a Chinese population. While several groups have reported the feasibility, efficacy, and safety of TAVI for patients with a BAV, worldwide experience of the technique is still limited, especially in China. Methods: From March 2013 to November 2014, high surgical risk or inoperable patients with symptomatic severe aortic stenosis (AS) who had undergone TAVI at our institution were selected for inclusion in our study. Results were compared between a BAV group and a tricuspid aortic valve (TAV) group. Results: Forty patients were included in this study, 15 (37.5%) of whom were identified as having a BAV. In the BAV group, the aortic valve area was smaller ((0.47±0.13) vs. (0.59±0.14) cm 2 ), the ascending aortic diameter was larger ((40.4±4.4) vs. (36.4±4.3) mm), and the concomitant aortic regurgitation was lower. No significant differences were found between the groups in the other baseline characteristics. No differences were observed either in the choice of access or valve size. The procedural success achieved in this study was 100%. There were no differences between groups in device success (86.7% vs. 88.0%), 30-d mortality (6.7% vs. 8.0%), or 30-d combined end point (13.3% vs. 12.0%). The incidences of new pacemaker implantation, paravalvular regurgitation and other complications, recovery of left ventricle ejection fraction and heart function were similar in both groups. Conclusions: Patients with a severely stenotic BAV can be treated with TAVI, and their condition after treatment should be similar to that of people with a TAV.
Introduction
Transcatheter aortic valve implantation (TAVI) has emerged as a promising treatment strategy for patients with severe symptomatic aortic stenosis (AS), whose condition has been carefully evaluated as being high surgical risk or inoperable patients (Leon et al., Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology) ISSN 1673-1581 (Print); ISSN 1862-1783 (Online) www.zju.edu.cn/jzus; www.springerlink.com E-mail: jzus@zju.edu.cn 2010; Smith et al., 2011; Adams et al., 2014) . Despite the great improvements achieved in recent years, unfortunately, TAVI for patients with a bicuspid aortic valve (BAV) is still deemed to be a relative contraindication because of the exclusion of these patients from most clinical trials (Leon et al., 2010; Smith et al., 2011) . One possible concern is the unfavorable anatomy of a BAV, which will result in elliptical deployment of a bioprosthesis, increase the procedural complications including residual aortic regurgitation, coronary obstruction, annulus rupture and aortic dissection, and decrease the durability of the bioprosthesis (Zegdi et al., 2008; Wijesinghe et al., 2010; Himbert et al., 2012) . However, BAV is the most common congenital heart disease, occurring in 0.5% to 2.0% of the general population (Roberts, 1970; Nistri et al., 2005; Tutar et al., 2005) , and has been observed in about 50% of aortic valves resected during surgical aortic valve replacement (SAVR) (Roberts and Ko, 2005) . Although several groups have reported the feasibility, efficacy, and safety of TAVI for patients with a BAV (Wijesinghe et al., 2010; Himbert et al., 2012; Hayashida et al., 2013; Bauer et al., 2014; Costopoulos et al., 2014; Kochman et al., 2014) , global experience of the procedure is lacking, especially in China.
The purpose of this study is to evaluate the safety and efficacy of TAVI in patients with a severe stenotic BAV in a Chinese population.
Subjects and methods
From March 2013, consecutive patients with symptomatic severe AS (valve area <1.0 cm 2 ), who had undergone TAVI at our institution, were prospectively included in this study. The inclusion criteria for candidates with TAVI included surgical high risk defined as logistic EuroSCORE ≥20%, or other risk factors not included in the risk scores (e.g. frailty, porcelain aorta, previous chest radiotherapy, and advanced age). The decision to proceed with TAVI was reviewed by a dedicated heart valve team, including experienced interventional cardiologists, general cardiologists, cardiac surgeons, anesthesiologists, and cardiac radiologists. Between March 2013 and November 2014, a total of 40 patients underwent TAVI, 15 (37.5%) of whom had a BAV.
According to a previous report (Hayashida et al., 2013) , BAVs are defined as having deformed aortic valves with two functional cusps forming a valve mechanism with less than three zones of parallel apposition between the cusps. BAVs are classified into three types depending on the number of raphes: type 0, valves with no raphes; type 1, valves with one raphe; and type 2, valves with two raphes (Sievers and Schmidtke, 2007) . Patients with functional BAVs due to commissural fusion in tricuspid aortic valves (TAVs) were not included in the BAV group. The diagnosis of BAV was made by imaging specialists through transthoracic echocardiography (TTE) and dualsource computed tomography (DSCT) in all cases.
As to procedure aspects, the selection of the transfemoral access or alternative approaches, including the subclavian artery and aorta, depended on the size, calcification, and tortuosity of the iliofemoral arterial access performed by a DSCT. The choices of general or local anesthesia, cutting down or puncture of vascular access were made according to each patient's condition and the operator's experience. Two valve prostheses, CoreValve (Medtronic Inc., Minneapolis, Minnesota, USA) in diameters of 23, 26, 29, and 31 mm and VENUS A (Venus Medtech, Hangzhou, China) in diameters of 23, 26, 29, and 32 mm, were used in this study. All patients received dual antiplatelet therapy daily before TAVI or were administered a loading dosage of 300 mg of clopidogrel and 300 mg of aspirin before the procedure. After the successful preparation of the vascular access, a bolus of intravenous heparin (70 IU/kg) was injected to achieve an activated clotting time of 250 to 300 s, which was checked and adjusted every 30 min thereafter. Clopidogrel at 75 mg/d was used for 3 to 6 months after the procedure and aspirin at 100 mg/d will be continued for life if there were no contraindications. Oral anticoagulation was administered if necessary. Follow-up data from all the patients were collected at 30 d, including clinical assessment, electrocardiography, and TTE data.
Clinical end points and device success were defined according to the standardized definitions for TAVI published by the Valve Academic Research Consortium . The main end points derived from this study were the all-cause 30-d mortality, a 30-d safety composite end point, and device success. The combined 30-d safety end points included all-cause mortality, major stroke, life-threatening bleeding, acute kidney injury stage 3 (including renal replacement therapy), periprocedural myocardial infarction, major vascular complications and repeated procedure for valve-related dysfunction (surgical or interventional therapy). Device success was defined as successful vascular access, delivery and deployment of a single prosthesis in the proper anatomical location, successful retrieval of the delivery system and intended performance of the prosthetic heart valve (aortic valve area >1.2 cm 2 and mean aortic valve gradient <20 mmHg or peak velocity <3 m/s, without moderate or severe prosthetic valve aortic regurgitation) .
Qualitative variables are expressed as numbers or percentages and quantitative variables as mean± standard deviation (SD). The unpaired Student's t-test or Wilcoxon rank-sum test was used to compare quantitative variables according to the variable's distribution. Qualitative variables were compared using the Fisher exact test. Statistical significance was defined as P<0.05. The data were analyzed using SPSS statistics 21.0 (SPSS Inc., Chicago, Illinois, USA). 
Results
From March 2013 to November 2014, a total of 40 patients with symptomatic severe AS undergoing TAVI were consecutively included in this study. Fifteen of these patients (37.5%) were identified as having a BAV by DSCT and TTE. The BAV group consisted of type 0 (11 cases) and type 1 (4 cases) according to previously described criteria (Sievers and Schmidtke, 2007 DSCT evaluation . No significant differences were found between the BAV and TAV groups in other baseline and clinical characteristics (Table 1) .
CoreValve was implanted in 72.5% of cases and VENUS A in the rest. The transfemoral approach was used in 90% of cases, a subclavian approach in only one patient and direct aortic access in three patients. A 29-mm prosthesis was most frequently applied, whether CoreValve or VENUS A. However, no difference was observed between the BAV and TAV groups in either the choice of access or the valve size (Table 2) .
A procedural success rate of 100% was achieved in this study. Device success was 86.8% in the BAV group and 88.0% in the TAV group (P=1.00), and the incidence of second valve implantation was similar in each group. New pacemakers were implanted in 5 patients (12.5%), 2 from the BAV group (13.3%) and 3 from the TAV group (12.0%). No annulus rupture, coronary occlusion or conversion to open heart surgery occurred. There were no significant differences between the two groups in bleeding, cerebrovascular accidents, major vascular complications, or myocardial infarction after the procedure. No acute kidney injury or new onset atrial fibrillation was observed in either group (Table 3 ).
All patients were followed up for one month. There were no differences between the two groups in the incidence of 30-d mortality (6.7% vs. 8.0%, P=1.00) or 30-d combined safety end point (12.5% vs. 12.0%, P=1.00) ( Table 3) . Clinical follow-up showed that the heart function status in both groups had obviously improved, and heart function with NYHA III was found in only one patient with TAV anatomy. Echocardiography showed no differences in aortic (Table 3) .
Discussion
In this study, the characteristics and clinical outcomes of patients with severe symptomatic BAV who underwent TAVI, were compared to those with a TAV. We found that the incidences of 30-d mortality, 30-d combined safety end point, and device success Bleeding (life threatening) 1 (2.5%) 0 (0%) 1 (4.0%) 1.00
Bleeding (major) 6 (15.0%) 1 (6.7%) 5 (20.0%) 0.49
Myocardial infarction 1 (2.5%) 1 (6.7%) 0 (0%) 0.38
Stroke 2 (5.0%) 1 (6.7%) 1 (4.0%) 1.00 minor 2 (5.0%) 1 (6.7%) 1 (4.0%) 1.00 major 0 (0%) 0 (0%) 0 (0%) 1.00
Major vascular complications 1 (2.5%) 1 (6.7%) 0 (0%) 0.38
Acute kidney injury 0 (0%) 0 (0%) 0 (0%) 1.00
New pacemaker 5 (12.5%) 2 (13.3%) 3 (12.0%) 1.00
New onset atrial fibrillation 0 (0%) 0 (0%) 0 (0%) 1.00
Valve-related dysfunction requiring repeat procedure 0 (0%) 0 (0%) 0 (0%) 1.00 Many studies and some case reports have demonstrated a positive effect of TAVI when used on BAV patients whose condition is inoperable or has a high surgical risk (Wijesinghe et al., 2010; Himbert et al., 2012; Hayashida et al., 2013; Bauer et al., 2014; Costopoulos et al., 2014; Kochman et al., 2014) . However, experience from Asian populations, especially from China, is scarce. To our knowledge, this is the first report to compare TAVI in severe AS patients with a BAV versus those with a TAV in a Chinese population. In view of the good performance of the TAVI procedure in patients with a BAV, our results indicate that TAVI can be safely and effectively applied to BAV patients in Chinese populations.
Similar to previous studies of the use of TAVI on patients with a BAV, no increase in complications, such as residual aortic regurgitation, coronary obstruction, annulus rupture, or aortic dissection, was observed in our study. To achieve satisfactory results from the procedure, the selection of the access route according to the anatomy and angulation, choice of balloon size for pre-dilation and valve size, consideration of the implanting depth and whether post-dilation should be used, and how to do the post-dilation are very important. However, no ideal software for the TAVI procedure is available to guide the selection of an appropriate valve for individuals, especially for patients with a BAV. Thus, the experience of the heart valve team and careful discussion before the procedure are crucial to avoid complications during the procedure.
As noted, the proportion of patients with a BAV (15 of 40, 37.5%) in this study was much higher than those of previous studies in Europe (3.0% to 9.2%) (Himbert et al., 2012; Hayashida et al., 2013; Bauer et al., 2014; Costopoulos et al., 2014; Kochman et al., 2014) . This phenomenon has also been observed in almost every center that performs TAVI in China, and in some centers as many as 50% of the patients who underwent TAVI had a BAV. Although functional BAVs due to commissural fusion of TAVs may be included in estimates in some centers, the proportion of true BAVs is actually very high in China. In this study, the percentage of BAVs with type 0 was 73.3%.
However, epidemic data on the prevalence of BAVs show that the percentage of patients with a severely stenotic BAV among all patients with severe AS is very low. Therefore, further epidemic investigations in the field of AS in Chinese populations are urgently needed.
Aortic dilation is frequently associated with BAV, and surgery of the ascending aorta is indicated in cases of ascending aortic diameter >45 mm when SAVR is scheduled or ascending aortic diameter >50 mm in the presence of other risk factors (Erbel et al., 2014) . In our study, patents with ascending aortic diameter >50 mm were excluded. Only two patients with ascending aortic diameter >45 mm (48.4 and 49.4 mm, respectively) were included. However, the surgical risk evaluation suggested these two patients were at high risk and surgery was not recommended by our heart valve team. Thus, careful follow-up of all the patients with aortic dilation should be applied and surgery will be considered when the aortic diameter increased very quickly in accordance with the suggestions of the heart valve team.
Limitations of this study include the small sample size and the short-term of the follow-up. Furthermore, data from only single center were collected, making it difficult to generalize about the use of TAVI for treating BAV patients. Multi-center registries with large samples and long-term follow-up results will make the conclusion more convincing.
In conclusion, in Chinese populations, patients with a severely stenotic BAV can be treated with TAVI, and their condition after treatment should be similar to that of patients with a TAV.
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